Latest revenue
$27.9M
as of 2026-03-31
Latest net income
$-19.0M
as of 2026-03-31
Net margin
-68.1%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $80.1M
- Enterprise value
- $80.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $21.98
- 52-wk low
- $3.00
- Beta
- —
- Shares out
- 18.5M
5-year trend
What this company does
Item 1. Business. Our Company Outset is a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity. We believe the Tablo® Hemodialysis System (Tablo) represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. We designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. Tablo is currently cleared by the U.S. Food and Drug Administration (FDA) for use in the hospital, clinic or home…
AI summary unavailable — showing raw filing excerpt
Generated from OM's filing dated 2026-02-13
Key risks
Item 1A. Risk Factors. Risk Factors Summary The following summarizes the principal factors that make an investment in our company speculative or risky, all of which are more fully described in the risk factors section below. This summary should be read in conjunction with the risk factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. The following factors could result in harm to our business, reputation, revenue, financial results, and prospects, among other impacts: Risks Related to Our Business and Industry •Our history of net losses and expectation that we will continue to incur losses; •Our ability to achieve sustainable gross…
AI summary unavailable — showing raw filing excerpt
Generated from OM's filing dated 2026-02-13
Profitability
Gross margin
39.1%
15.4%Operating margin
-55.8%
44.0%Net margin
-68.3%
39.3%Return on equity
-64.3%
38.2%Return on assets
-30.9%
33.5%Leverage
Debt / equity
1.08×
12.9%Long-term debt / equity
0.76×
52.8%Debt / assets
52.0%
6.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $27.9M | -6.3% | $-19.0M | +26.4% | -68.1% |
Q4 2025 2025-12-31 | $28.9M | -2.0% | $-19.5M | +24.0% | -67.5% |
Q3 2025 2025-09-30 | $29.4M | +2.7% | $-17.8M | +36.2% | -60.6% |
Q2 2025 2025-06-30 | $31.4M | +14.7% | $-18.5M | +46.2% | -59.0% |
Q1 2025 2025-03-31 | $29.8M | +5.6% | $-25.8M | +35.5% | -86.7% |
Q4 2024 2024-12-31 | $29.5M | — | $-25.6M | — | -87.0% |
Q3 2024 2024-09-30 | $28.7M | -5.6% | $-27.9M | +39.5% | -97.5% |
Q2 2024 2024-06-30 | $27.4M | -24.0% | $-34.5M | +21.8% | -125.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on OM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$255.0K
Net activity
−$255.0K
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns OM
Institutional value
$24.6M
Total shares held
6.5M
Distinct holders
55
-44 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BML Capital Management, LLC | 1.9M | $7.3M | +1.4M (+250.2%) | Added |
| 2 | BlackRock, Inc. | 1.3M | $4.9M | -26.1K (-2.0%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 763.8K | $2.9M | — | New |
| 4 | Ensign Peak Advisors, Inc | 526.6K | $2.0M | -33.6K (-6.0%) | Trimmed |
| 5 | Assenagon Asset Management S.A. | 504.1K | $1.9M | -4.3K (-0.8%) | Trimmed |
| 6 | UBS Group AG | 252.5K | $969.6K | +179.3K (+245.1%) | Added |
| 7 | Stratos Wealth Partners, LTD. | 200.5K | $770.1K | — | New |
| 8 | DIMENSIONAL FUND ADVISORS LP | 113.4K | $435.0K | -45.0K (-28.4%) | Trimmed |
| 9 | VANGUARD FIDUCIARY TRUST CO | 111.6K | $428.7K | — | New |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 98.6K | $378.7K | — | New |
| 11 | JPMORGAN CHASE & CO | 101.0K | $364.5K | -8.4K (-7.7%) | Trimmed |
| 12 | PURA VIDA INVESTMENTS, LLC | 83.3K | $320.0K | +78.3K (+1566.7%) | Added |
| 13 | BANK OF MONTREAL /CAN/ | 18.0K | $265.0K | — | New |
| 14 | Nuveen, LLC | 65.6K | $251.8K | +281 (+0.4%) | Added |
| 15 | JANE STREET GROUP, LLC | 64.8K | $248.9K | +38.6K (+146.9%) | Added |
| 16 | Bank of New York Mellon Corp | 62.4K | $239.5K | +2.4K (+4.1%) | Added |
| 17 | BNP PARIBAS FINANCIAL MARKETS | 42.9K | $164.9K | +30.9K (+257.3%) | Added |
| 18 | SEI INVESTMENTS CO | 35.4K | $135.8K | +4.7K (+15.5%) | Added |
| 19 | DEUTSCHE BANK AG\ | 30.4K | $116.7K | -147.3K (-82.9%) | Trimmed |
| 20 | RHUMBLINE ADVISERS | 21.6K | $82.9K | +658 (+3.1%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once OM's latest filing finishes processing.